Vise Technologies Inc. Buys 8,121 Shares of Eli Lilly and Company $LLY

Vise Technologies Inc. boosted its stake in Eli Lilly and Company (NYSE:LLY) by 52.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 23,558 shares of the company’s stock after purchasing an additional 8,121 shares during the quarter. Vise Technologies Inc.’s holdings in Eli Lilly and Company were worth $25,317,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in LLY. Cidel Asset Management Inc. boosted its position in Eli Lilly and Company by 26.5% during the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company’s stock valued at $20,392,000 after purchasing an additional 5,591 shares during the last quarter. Spire Wealth Management boosted its position in Eli Lilly and Company by 2.2% during the fourth quarter. Spire Wealth Management now owns 27,719 shares of the company’s stock valued at $29,789,000 after purchasing an additional 592 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in shares of Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company’s stock valued at $32,365,000 after buying an additional 8,659 shares during the last quarter. Farther Finance Advisors LLC lifted its position in shares of Eli Lilly and Company by 30.8% in the fourth quarter. Farther Finance Advisors LLC now owns 31,145 shares of the company’s stock valued at $33,471,000 after buying an additional 7,338 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its position in shares of Eli Lilly and Company by 3.5% in the third quarter. Teachers Retirement System of The State of Kentucky now owns 165,165 shares of the company’s stock valued at $126,022,000 after buying an additional 5,595 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: CVS Health’s latest move is being seen as another win for Eli Lilly’s LillyDirect ecosystem, strengthening its position in the chronic weight-management market and potentially expanding access to patients using Lilly’s obesity treatments. Article Title
• Positive Sentiment: WW International said its WeightWatchers Med+ program is now available through LillyDirect, which could help broaden the reach of GLP-1-based weight-loss care and reinforce demand around Eli Lilly’s obesity franchise. Article Title
• Positive Sentiment: Eli Lilly’s $1.9 billion partnership with Ascidian Therapeutics adds another growth avenue outside obesity, signaling continued investment in genetic medicine and kidney-disease therapies that could diversify future revenue. Article Title
• Positive Sentiment: Multiple commentary pieces highlighted Lilly as a buy and noted continued strength in its obesity, gene-editing, vaccine, and cancer pipelines, which may be supporting investor sentiment. Article Title
• Neutral Sentiment: Several market-watchlist and “stock of the day” articles kept Eli Lilly in the spotlight, but they did not add material new fundamentals beyond broader bullish coverage. Article Title
• Negative Sentiment: The Ascidian deal was also reported alongside a stock dip in one headline, suggesting some investors may be cautious about the size of Lilly’s acquisition and partnership spending even as they like the strategic logic. Article Title

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $1,125.00 on Friday. The stock’s fifty day moving average price is $970.24 and its two-hundred day moving average price is $1,012.19. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,149.10. The company has a debt-to-equity ratio of 1.26, a current ratio of 1.50 and a quick ratio of 1.10. The firm has a market cap of $1.06 trillion, a PE ratio of 39.96, a price-to-earnings-growth ratio of 1.18 and a beta of 0.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, April 30th. The company reported $8.55 EPS for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter last year, the company earned $3.34 EPS. The company’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, research analysts expect that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be paid a $1.73 dividend. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. raised their price objective on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Daiwa Securities Group increased their target price on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Barclays increased their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. HSBC lowered Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their target price for the stock from $1,070.00 to $850.00 in a research note on Tuesday, March 17th. Finally, UBS Group restated a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $1,227.00.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.